Cyber Clean awarded ‘The Hottest Product’ title at the National Association of Chain Drug Stores Marketplace Conference
CHERRY HILL, N.J. Cyber Clean was named “The Hottest Product” trend at the 2009 National Association of Chain Drug Stores Marketplace Conference on June 29 in Boston, Mass.
The NACDS Marketplace Conference is the largest meeting of drug, food, mass, club and value retailing in the United States. Over 270 retail companies gathered at the event to represent over 145,000 retail outlets, as well as $500 billion in annual buying power.
Senior executives from both retail and manufacturing companies came together to assess the impact in the marketplace of products, programs and price-providing exhibitors.
“To be recognized at the most influential business meeting of the year among retailers and exhibitors is an honor,” said Alan Sutton, Cyber Clean CEO. “This demonstrates Cyber Clean’s ability to stand out among traditional cleaning products and hopefully has proven to retailers that it is an essential product in our current health-conscious environment.”
Cyber Clean is a cleaning product developed to catch dirt and kill germs on all devices and surfaces. The gel-like product is also good for the environment with its reusable and biogradable format.
Report: Card-check provision removed from Employee Free Choice Act
NEW YORK The New York Times on Friday reported that the “card-check provision” — which would have required employers to recognize a union as soon as a majority of workers signed cards saying they wanted a union as opposed to a secret-ballot election — has been removed from the Employee Free Choice Act in an effort to secure enough Democratic votes to avoid a filibuster.
It was a polarizing issue — the card-check provision was advocated by union organizations because it would have made it easier to unionize a workforce. In its place, several Senate and labor officials told the New York Times, the revised bill would require shorter unionization campaigns and faster elections — with elections to be held within two work-weeks after 30% of a workforce signed cards favoring unionization.
Gilead enters partnership with Tibotec to develop HIV drug
FOSTER CITY, Calif. Gilead Sciences said it entered a partnership with Tibotec Pharmaceuticals to develop a single daily antiretroviral HIV pill.
The proposed drug would combine Gilead’s Truvada with a drug Tibotec is developing called TMC278, or rilpivirine. Terms were not disclosed, but Gilead said it would take the lead in manufacturing and testing the combined drug, working to get it approved by regulators, and selling it.
Gilead said the product would be the second complete antiretroviral treatment for HIV available in one pill. The first is Gilead’s Atripla, which combines three HIV drugs. The company said the combined pills make treatment simpler for patients.
Tibotec, a unit of Johnson & Johnson, would be responsible for developing rilpivirine as a standalone drug.